SATELLITE MEETING: ACCESS TO AIDS TREATMENT AND INTELLECTUAL

1
SATELLITE MEETING



ACCESS TO AIDS TREATMENT AND INTELLECTUAL
PROPERTYON BRAZIL, SOUTH AFRICA, CHINA, INDIA,
THAILAND AND COLOMBIA.August 5th 2008.

Francisco Rossi
2

CIVIL SOCIETY PARTICIPATION AND THE KALETRA CASE
IN COLOMBIA.
3
HIV AIDS IN COLOMBIA

• Concentrated epidemic.
• Prevalence around 0,7
• 47.000 cases in 22 years
• 172.000 PLHIV estimated
• Around 16.000 people on treatment.
• 72 coverage on HAART

4
IPR ON PHARMACEUTICALS IN COLOMBIA

• Balance between IPR protection
• and public health
• TRIPS introduction in 2003 (Decission 486 Andean
  Community)
• Data protection 2003
• USA Colombia FTA

5
IPR ON PHARMACEUTICALS IN COLOMBIA

• Balance between IPR protection
• and public health
• No balance
• Prices out of the possibilities of average
  population
• Third payer to create a market
• Public System
• Insurance Systems
• Big Charity
• Mechanisms to Move to the patient the pressure
  of high prices

6
KALETRA PATENT

• Granted after a long controversy for 9 years
• Linkage (with no FTA)
• Enforced by Judicial Autorities
• Enforced By health Authorities

7
KALETRA PATENT
8
KALETRA PATENT
EMTRICITABINE
LAMIVUDINE
9
EFFECTS OF PATENTS ON ACCESS

• Higher prices
• High investments on marketing
• Innovative mechanisms to Transfer the pressure
  to patients

10
KALETRA PRICES
Source PAHO-CHU Negotiation of ARVs 2005.
11
KALETRA PRICES
Source PAHO-CHU Negotiation of ARVs 2005.
12
KALETRA PRICES
Source PAHO-CHU Negotiation of ARVs 2005.
13
KALETRA CONSUMPTION
14
Innovative mechanisms to Transfer the pressure
to patients

• Geographical barriers
• Time consuming Barriers
• Exception Mechanisms Public defender survey
• Stigma and discrimination

15

• COMPULSORY LICENSE FOR KALETRA IN COLOMBIA
• Public Interest for private use
• Open License
• Competition price reductions

16
EPILOG

• Reducing price from 1.6 to 0.6
• Offers from Cipla, Rambaxi, Matrix and some
  National producers
• Savings equal to 9.000 first line treatments
• CSOs empowerment

17
EPILOG

• Two organizations, out of 15 retired from the
  table of CSOs on HIV.
• unexpected reaction from doctors quality of
  generics.
• Limited disclosure on the media
• Impressive international support
• Impressive Answer from government

18
(No Transcript)